Markets:

Overview

News

Currencies

International

Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

107.45 +1.43 (+1.35%)

Streaming Delayed Price Updated: 2:19 PM EDT, Mar 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

November 09, 2021

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 08, 2021

- On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 - Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the...

From Celcuity Inc.

Via AccessWire

Topics Intellectual Property

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

October 29, 2021

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases

October 18, 2021

From Celcuity Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 ↗

September 07, 2021

Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗

October 08, 2021

Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:

Via Benzinga

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 09, 2021

- Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities - After follow-on offering,...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

August 05, 2021

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

August 02, 2021

MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the William Blair Biotech Focus Conference

July 08, 2021

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

58 Biggest Movers From Yesterday ↗

June 30, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) stock moved upwards by 93.55% to $24.33 during Tuesday's regular session. As of 12:30 EST, this security is trading at...

Via Benzinga

35 Stocks Moving In Tuesday's Mid-Day Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231...

Via Benzinga

Why Celcuity Stock Is Crashing Today ↗

June 29, 2021

The clinical-stage biotech announced the pricing of a secondary stock offering.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2....

Via Benzinga

22 Stocks Moving in Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to...

Via Benzinga

Celcuity Announces Pricing of Follow-on Offering

June 28, 2021

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

Topics Regulatory Compliance

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 28, 2021

Gainers SCWorx (NASDAQ:WORX) shares rose ...

Via Benzinga

Celcuity Announces Launch of Follow-on Offering

June 28, 2021

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

Topics Regulatory Compliance

45 Biggest Movers From Yesterday ↗

June 25, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads...

Via Benzinga

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗

June 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations

June 09, 2021

MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq ↗

May 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,...

Via Benzinga

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 10, 2021

- Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer - Announced...

From Celcuity Inc.

Via AccessWire

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping ↗

April 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.